

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

PW MEDTECH GROUP LIMITED

普 华 和 顺 集 团 公 司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1358)

CHANGE OF NON-EXECUTIVE DIRECTOR AND REMUNERATION COMMITTEE MEMBER

The Board announces the following changes in the Company with effect from 20 March 2015:

- (1) Mr. Feng Dai has resigned as a non-executive director and a member of the remuneration committee of the Board; and
- (2) Mr. Fang Min has been appointed as a non-executive director and a member of the remuneration committee of the Board.

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The board of directors (the “**Board**”) of PW Medtech Group Limited (the “**Company**”) announces that Mr. Feng Dai has resigned as a non-executive director of the Company with effect from 20 March 2015 due to his intended pursuit of other business commitments. Following his resignation as a non-executive director, he has also ceased acting as a member of the remuneration committee of the Board.

Mr. Feng has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Feng for his valuable contributions to the Company.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board is also pleased to announce that Mr. Fang Min has been appointed as a non-executive director of the Company and a member of the remuneration committee of the Board with effect from 20 March 2015.

The biographical details of Mr. Fang are set out as follows:

Mr. Fang Min, aged 35, is a non-executive director of the Company and a member of the remuneration committee of the Board. In addition to his above positions, Mr. Fang has been a principal of Beijing Warburg Pincus Investment Consulting Company Limited, Shanghai Branch (“**Warburg Pincus**”, an affiliate of WP X Asia Medical Devices Holdings Limited, which is one of the Company’s substantial shareholders) since July 2011, and a core member of its China healthcare team. Mr. Fang has been a director of China Biological Products, Inc. (a company listed on NASDAQ, symbol: CBPO) since March 2015. Mr. Fang also serves on the board of several private companies including EA, Inc. (時代天使生物科技有限公司) and Beijing Amcare Women’s and Children’s Hospital Co., Ltd. (北京美中宜和婦兒醫院有限公司). From March 2010 to July 2011, he was a vice president at Carlyle Asia Private Equity. From July 2007 to February 2010, Mr. Fang was an associate at Warburg Pincus. Prior to joining Warburg Pincus, he worked at The Boston Consulting Group focusing on providing management consultancy for pharmaceutical and medical device companies from September 2001 to June 2005. Mr. Fang received a B.A. of International Finance from Fudan University in June 2001 and an M.B.A. from the Stanford Graduate School of Business in June 2007.

Save as disclosed above, Mr. Fang has not held other directorships in the last three years in public companies the securities of which are listed on any securities market in Hong Kong or overseas.

The Company has issued a letter of appointment to Mr. Fang for a term of office of 3 years from 20 March 2015, unless terminated by either party giving to the other not less than 3 months’ prior notice in writing. In accordance with the articles of association of the Company (the “**Articles of Association**”), Mr. Fang will hold office only until the first general meeting of the Company after his appointment and be subject to re-election at such meeting. Upon his re-election at such meeting, he is also subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the Articles of Association.

As far as the directors of the Company are aware, save as disclosed in this announcement, Mr. Fang does not have any relationships with other directors, senior management, substantial shareholders (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, the “**Listing Rules**”), or controlling shareholders (as defined in the Listing Rules) of the Company.

As far as the directors of the Company are aware, Mr. Fang was not interested or deemed to be interested in any shares or underlying shares of the Company pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Mr. Fang is not entitled to any director’s fee. He is eligible to participate in the Company’s share option scheme. The emoluments of Mr. Fang are subject to revision in future by the decision of the Board based on the recommendation of the remuneration committee of the Board.

As far as the directors of the Company are aware, there is no information of Mr. Fang to be disclosed pursuant to any of the requirements under paragraphs 13.51(2)(h) to 13.51(2)(v) of the Listing Rules; and there are no other matters concerning Mr. Fang that need to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to welcome Mr. Fang in joining the Board.

By Order of the Board
PW Medtech Group Limited
Yue'e Zhang
Chairman

Hong Kong, 20 March 2015

As at the date of this announcement, the Board comprises two executive directors, namely, Ms. Yue'e Zhang and Mr. Jiang Liwei; two non-executive directors, namely, Mr. Lin Junshan and Mr. Fang Min; and three independent non-executive directors, namely, Mr. Zhang Xingdong, Mr. Wang Xiaogang and Mr. Chen Geng.